Nanobody-drug conjugates (NDCs) are gaining momentum as next-generation targeted therapies, offering improved tissue penetration and faster clearance compared to traditional antibodies. These novel biologics demand a unique combination of biologics, chemistry, and conjugation expertise — making specialized NDC CDMO companies essential partners in their development.
As an evolution of ADCs, NDCs present specific formulation, scalability, and regulatory challenges. Collaborating with experts in nanobody-drug conjugate contract manufacturing ensures the necessary infrastructure, compliance, and technical know-how are in place to move from discovery through clinical and commercial production.